Abstract
Group IV cytosolic phospholipase A2 (cPLA2α) plays a critical role in inflammatory processes. It produces arachidonic acid which is the main source of the pro-inflammatory eicosanoids mediators that are important in innate immune system. In some cases, these proinflammatory mediators cause damages to the host tissues and therefore promote autoimmune diseases. Consequently, development of potent inhibitors against cPLA2α could improve the therapy of inflammatory diseases. In the last two decades, intense efforts have been done to find potent cPLA2α inhibitors. Several scaffolds have been developed with the use of structureactivity relationship (SAR) studies, and potent inhibitors have been obtained. The poor absorption of these compounds from intestine was the main challenge for clinical application. This review illustrates the search for cPLA2α inhibitors, their SAR studies and biological effects.
Keywords: Cytosolic phospholipase A2α, inflammation, anti-inflammatory, cPLA2α inhibitors, structure-activity relationship, arachidonic acid.
Current Medicinal Chemistry
Title:Targeting Cytosolic Phospholipase A2α for Novel Anti-Inflammatory Agents
Volume: 25 Issue: 21
Author(s): Jalal Soubhye*, Pierre van Antwerpen and Francois Dufrasne
Affiliation:
- Department of Pharmacognosy, Bioanalysis and Drug Discovery, Faculty of Pharmacy, Université Libre de Bruxelles (ULB), Boulevard du Triomphe, 1050 Bruxelles,Belgium
Keywords: Cytosolic phospholipase A2α, inflammation, anti-inflammatory, cPLA2α inhibitors, structure-activity relationship, arachidonic acid.
Abstract: Group IV cytosolic phospholipase A2 (cPLA2α) plays a critical role in inflammatory processes. It produces arachidonic acid which is the main source of the pro-inflammatory eicosanoids mediators that are important in innate immune system. In some cases, these proinflammatory mediators cause damages to the host tissues and therefore promote autoimmune diseases. Consequently, development of potent inhibitors against cPLA2α could improve the therapy of inflammatory diseases. In the last two decades, intense efforts have been done to find potent cPLA2α inhibitors. Several scaffolds have been developed with the use of structureactivity relationship (SAR) studies, and potent inhibitors have been obtained. The poor absorption of these compounds from intestine was the main challenge for clinical application. This review illustrates the search for cPLA2α inhibitors, their SAR studies and biological effects.
Export Options
About this article
Cite this article as:
Soubhye Jalal *, van Antwerpen Pierre and Dufrasne Francois , Targeting Cytosolic Phospholipase A2α for Novel Anti-Inflammatory Agents, Current Medicinal Chemistry 2018; 25 (21) . https://dx.doi.org/10.2174/0929867325666180117103919
DOI https://dx.doi.org/10.2174/0929867325666180117103919 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Dendritic Cells in Autoimmune Liver Diseases
Current Immunology Reviews (Discontinued) CCR2 Antagonists
Current Topics in Medicinal Chemistry Molecular Field Analysis (MFA) and Other QSAR Techniques in Development of Phosphatase Inhibitors
Anti-Cancer Agents in Medicinal Chemistry Erythropoietin Directly Affects Human Macrophage Functionality
Current Pharmaceutical Biotechnology The Role of Autophagy in Rheumatic Disease
Current Drug Targets Lymphoid-Specific Tyrosine Phosphatase (Lyp): A Potential Drug Target For Treatment of Autoimmune Diseases
Current Drug Targets Myelin Sheaths and Autoimmune Response Induced by Myelin Proteins and Alphaviruses. I. Physicochemical Background
Current Medicinal Chemistry A Potential Therapeutic Target RNA-binding Protein, Arid5a for the Treatment of Inflammatory Disease Associated with Aberrant Cytokine Expression
Current Pharmaceutical Design Experimental Strategies in Autoimmunity: Antagonists of Cytokines and their Receptors, Nanocarriers, Inhibitors of Immunoproteasome, Leukocyte Migration and Protein Kinases
Current Pharmaceutical Design Danger-Detector NKG2D: Immunosurveillance of Induced Self and Modulation by Cytokines and Soluble Ligands
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Thrombotic Management of Antiphospholipid Syndrome: Towards Novel Targeted Therapies
Current Vascular Pharmacology Therapeutic Approach to Multiple Sclerosis by Novel Oral Drugs
Recent Patents on Inflammation & Allergy Drug Discovery The Central Role of Angiotensin I-Converting Enzyme in Vertebrate Pathophysiology
Current Topics in Medicinal Chemistry Thrombotic Microangiopathies: Towards a Pathophysiology-Based Classification
Cardiovascular & Hematological Disorders-Drug Targets NF-κB in Type 1 Diabetes
Inflammation & Allergy - Drug Targets (Discontinued) Immuno - Functionalized Silver Nanoparticles for Diagnostics, Therapeutics and Protection of Rabies Viral Infection
Current Nanomedicine A New Drug Candidate (GEMSP) for Multiple Sclerosis
Current Medicinal Chemistry Mesenchymal Stromal Cells; Role in Tissue Repair, Drug Discovery and Immune Modulation
Current Drug Delivery DNA Vaccines: A Mini Review
Recent Patents on DNA & Gene Sequences Recent Advances in Regulatory T Cell Therapy of Autoimmunity, Graft Rejection and Cancer
Recent Patents on Inflammation & Allergy Drug Discovery